225 related articles for article (PubMed ID: 14621993)
1. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
2. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
3. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
4. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB.
Wolff B; Naumann M
Oncogene; 1999 Apr; 18(16):2663-6. PubMed ID: 10353611
[TBL] [Abstract][Full Text] [Related]
5. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.
Dreyfus DH; Nagasawa M; Gelfand EW; Ghoda LY
BMC Immunol; 2005 Jun; 6():12. PubMed ID: 15969767
[TBL] [Abstract][Full Text] [Related]
6. Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity.
Li J; Li H; Tsai MD
Biochemistry; 2003 Jun; 42(22):6921-8. PubMed ID: 12779347
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A.
Li J; Byeon IJ; Ericson K; Poi MJ; O'Maille P; Selby T; Tsai MD
Biochemistry; 1999 Mar; 38(10):2930-40. PubMed ID: 10074345
[TBL] [Abstract][Full Text] [Related]
8. The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner.
Li J; Melvin WS; Tsai MD; Muscarella P
Biochemistry; 2004 Apr; 43(14):4394-9. PubMed ID: 15065884
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
10. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb.
Li J; Tsai MD
Biochemistry; 2002 Mar; 41(12):3977-83. PubMed ID: 11900540
[TBL] [Abstract][Full Text] [Related]
11. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4.
Li J; Poi MJ; Qin D; Selby TL; Byeon IJ; Tsai MD
Biochemistry; 2000 Feb; 39(4):649-57. PubMed ID: 10651629
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
Phelps DE; Xiong Y
Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.
Boice JA; Fairman R
Protein Sci; 1996 Sep; 5(9):1776-84. PubMed ID: 8880901
[TBL] [Abstract][Full Text] [Related]
16. [Effect of lovastatin on the expression of IkappaBalpha and cell-cycle regulating protein in MCF-7 cells].
Wei N; Mi MT; Zhang QY; Yang ZX
Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):332-4. PubMed ID: 12921559
[TBL] [Abstract][Full Text] [Related]
17. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.
Ragione FD; Russo GL; Oliva A; Mercurio C; Mastropietro S; Pietra VD; Zappia V
J Biol Chem; 1996 Jul; 271(27):15942-9. PubMed ID: 8663131
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
Jeffrey PD; Tong L; Pavletich NP
Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
[TBL] [Abstract][Full Text] [Related]
20. The IkappaBalpha/NF-kappaB complex has two hot spots, one at either end of the interface.
Bergqvist S; Ghosh G; Komives EA
Protein Sci; 2008 Dec; 17(12):2051-8. PubMed ID: 18824506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
